NCT06859515Recruiting
A Long-term Follow up Study of EXG102-031 in Participants With wAMD
A Long-term Follow-up Study to Evaluate the Injection of EXG102-031 Ophthalmic Injection in Participants With Wet Age-related Macular Degeneration (wAMD).
Source: ClinicalTrials.gov · Last updated 15 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 42 (estimated)
- First submitted
- 28 Feb 2025
- Start date
- 13 Mar 2025
- Primary completion date
- 15 May 2030
- Lead sponsor
- Guangzhou Jiayin Biotech Ltd
- Diseases
- Macular degeneration
- NCT number
- NCT06859515
What you commit to
- Study type: Observational
- Planned participants: 42
- From 13 Mar 2025 to the primary completion date, 15 May 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\. Paticipantes are unwilling or unable to participate in long-term follow-up
Who the study is looking for
- Previously received treatment with EXG102-031 in the study (EXG102-031-111);
- Paticipantes are informed consent and willingness to follow protocol procedures.
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.